Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial.

被引：0
|
作者：
Socinski, M. A.
Novello, S.
Sanchez, J. M.
Brahmer, J. A.
Govindan, R.
Belani, C. P.
Atkins, J. N.
Gillenwater, H. H.
Palleres, C.
Chao, R. C.
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Turin, I-10124 Turin, Italy
[3] Hosp Germans Trias & Pujol, Barcelona, Spain
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA
[7] SE Med Oncol, Goldsboro, NC USA
[8] Univ Virginia, Charlottesville, VA USA
[9] Hosp San Pablo, Barcelona, Spain
[10] Pfizer, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：364S / 364S
页数：1
相关论文
共 50 条
  • [31] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    LUNG CANCER, 2005, 49 : S242 - S242
  • [32] Efficacy and pharmacogenomic correlation of the combination of oxaliplatin and paclitaxel in first line advanced non-small cell lung cancer (NSCLC).: Preliminary results of the Spanish Lung Cancer Group (SLCG) 0103 phase II trial.
    Garrido Lopez, P.
    Isla, D.
    Gil, B.
    Lopez-Brea, M.
    Lianes, P.
    Gonzalez Larriba, J.
    Medina, B.
    Sanchez Ronco, M.
    Taron, M.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 394S - 394S
  • [33] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [34] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [35] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC)
    Han, J.
    Lee, S.
    Yun, T.
    Moon, Y.
    Park, I.
    Kim, H.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Efficacy of gefitinib in previously treated patients with advanced non-small-cell lung cancer: Phase II, multicenter study
    Park, Hee Sun
    Lee, Ki
    Jeon, Young June
    Kim, Young Chul
    Jang, Tae Won
    Jung, Maan Hong
    Son, Choon Hee
    Lee, Kwan Ho
    Kim, Ju Ock
    Kim, Sun Young
    ANNALS OF ONCOLOGY, 2006, 17 : 234 - 234
  • [38] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [39] Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
    Garon, E. B.
    Dubinett, S. M.
    Kabbinavar, F. F.
    Reckamp, K. L.
    Marquez-Garban, D. C.
    Goodglick, L.
    Sharma, S.
    Stabile, L. P.
    Siegfried, J.
    Pietras, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Combination gemcitabine and oxaliplatin for advanced non small cell lung cancer (NSCLC): An Australian multicenter randomized phase II sequencing trial.
    Broad, A
    Links, M
    Rosenthal, MA
    Mitchell, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 681S - 681S
12345